GSK's shares have experienced an unstable period, with frequent fluctuations due to various factors. The company recently faced a significant challenge with 70,000 Zantac lawsuits allowed to proceed, causing a 9% decline in stocks. The Zantac court rulings further upset the company's stocks. However, GSK won a
key legal battle over Ranitidine amidst the turmoil. The news about
CDC narrowing the age recommendation for RSV Shots also affected the stock negatively. On the positive side, GSK shares saw some increment after good Q2 results and crucial legal news. Furthermore, GSK also raised their profit outlook based on strong vaccine and HIV drug sales. The company consolidated its position by selling the last Haleon Shares for $1.58 Bln. After a plunge due to Delaware ruling, GSK
appealed the court's decision in the Zantac cases. The company's stock also benefitted from an EU backing on expanding RSV shot. Lastly, an unexpected twist happened when GSK's CEO projected the RSV vaccine revenue to top 1 bln pounds in the first year.
GSK Stocks News Analytics from Thu, 30 Nov 2023 08:00:00 GMT to Sat, 17 Aug 2024 06:32:38 GMT -
Rating -3
- Innovation 2
- Information 7
- Rumor -3
